Free Trial
NASDAQ:CING

Cingulate (CING) Stock Price, News & Analysis

Cingulate logo
$4.48 +0.38 (+9.27%)
(As of 11/20/2024 ET)

About Cingulate Stock (NASDAQ:CING)

Key Stats

Today's Range
$4.28
$5.02
50-Day Range
$3.36
$5.94
52-Week Range
$1.80
$152.40
Volume
445,611 shs
Average Volume
198,293 shs
Market Capitalization
$14.38 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.00
Consensus Rating
Moderate Buy

Company Overview

Cingulate Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company's stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults. It also focuses on developing CTx-2103 that is in a formulation stage for the treatment of anxiety. The company was founded in 2012 and is headquartered in Kansas City, Kansas.

Cingulate Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
53rd Percentile Overall Score

CING MarketRank™: 

Cingulate scored higher than 53% of companies evaluated by MarketBeat, and ranked 664th out of 963 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Cingulate has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Cingulate has only been the subject of 1 research reports in the past 90 days.

  • Read more about Cingulate's stock forecast and price target.
  • Percentage of Shares Shorted

    4.35% of the float of Cingulate has been sold short.
  • Short Interest Ratio / Days to Cover

    Cingulate has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Cingulate has recently increased by 132.90%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Cingulate does not currently pay a dividend.

  • Dividend Growth

    Cingulate does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    4.35% of the float of Cingulate has been sold short.
  • Short Interest Ratio / Days to Cover

    Cingulate has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Cingulate has recently increased by 132.90%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Cingulate has a news sentiment score of 0.61. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.45 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 6 news articles for Cingulate this week, compared to 3 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Cingulate insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    17.06% of the stock of Cingulate is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    41.31% of the stock of Cingulate is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Cingulate's insider trading history.
Receive CING Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cingulate and its competitors with MarketBeat's FREE daily newsletter.

CING Stock News Headlines

Cingulate upgraded to Buy from Hold at Maxim
2025 AI Stock Picks: 2 Hidden Gems Under $10/Share
The AI sector continues to make waves as we move into 2025, and now is a prime opportunity to get involved—without stretching your budget! We’ve just uncovered 2 promising AI stocks trading for under $10/share, and they’re positioned for impressive growth in the coming months.
Zacks Small Cap Predicts Stronger Earnings for Cingulate
CING: Third Quarter Results
Cingulate sees cash runway into 3Q25
See More Headlines

CING Stock Analysis - Frequently Asked Questions

Cingulate's stock was trading at $7.65 at the beginning of the year. Since then, CING shares have decreased by 41.4% and is now trading at $4.48.
View the best growth stocks for 2024 here
.

Cingulate Inc. (NASDAQ:CING) released its earnings results on Thursday, November, 7th. The company reported ($1.83) earnings per share for the quarter, beating analysts' consensus estimates of ($2.22) by $0.39.

Cingulate shares reverse split on Thursday, November 30th 2023. The 1-20 reverse split was announced on Thursday, November 30th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, November 30th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Cingulate (CING) raised $29 million in an initial public offering (IPO) on Wednesday, December 8th 2021. The company issued 4,166,666 shares at a price of $6.00-$8.00 per share.

Top institutional shareholders of Cingulate include Jane Street Group LLC (0.66%). Insiders that own company stock include Peter J Werth, Gregg Wm Givens, Jennifer L Callahan, Shane J Schaffer, Craig S Gilgallon, Curtis Medeiros, Horn Louis G Van and Laurie Myers.
View institutional ownership trends
.

Shares of CING stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Cingulate investors own include NVIDIA (NVDA), Windtree Therapeutics (WINT), AMC Entertainment (AMC), Sonnet BioTherapeutics (SONN), ARMOUR Residential REIT (ARR), BioCardia (BCDA) and Altamira Therapeutics (CYTO).

Company Calendar

Last Earnings
11/07/2024
Today
11/20/2024
Fiscal Year End
12/31/2024
Next Earnings (Estimated)
4/07/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:CING
Fax
N/A
Employees
13
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$8.00
High Stock Price Target
$8.00
Low Stock Price Target
$8.00
Potential Upside/Downside
+78.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
3 Analysts

Profitability

Net Income
$-23,530,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
($70.63) per share

Miscellaneous

Free Float
2,664,000
Market Cap
$14.39 million
Optionable
Not Optionable
Beta
-0.89
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

This page (NASDAQ:CING) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners